Roche CEO on New Drugs to Offset Post-Covid Drop

The video discusses Roche's strong Q1 performance, driven by new drugs excluding COVID products. The CEO, a long-time company veteran, emphasizes innovation and pipeline development as key focuses. Fabismo, a new medicine for severe eye disease, shows promising sales potential. Roche's diversified portfolio includes leadership in multiple sclerosis and hemophilia. Despite some setbacks in cancer and Alzheimer's treatments, Roche remains committed to innovation with 83 potential new medicines in the pipeline. The CEO addresses investor concerns, highlighting the inherent risks in pharma and the need for continued innovation.

What is the expected peak sales potential for the medicine Fabismo?

What challenges does Roche face regarding its pipeline and new medicines?

How does Roche plan to address investor concerns regarding its share price performance?